Second-line treatment of first relapse recurrent ovarian cancer.

摘要: First-line therapy of advanced ovarian cancer involves primary cytoreductive surgery and adjuvant systemic chemotherapy. Progression incompletely resected disease or recurrence after cytoreduction is inevitable. The approach to second-line treatment ill-defined chemotherapy remains the conventional approach, with being reserved in some patients debulk palliate symptoms. Increasing evidence suggests that secondary improves progression-free overall survival. This may be appropriate selected patients. Intraperitoneal delivered setting postoperatively has been shown more effective than surgery. However, its use not well accepted adopted Hyperthermic intraperitoneal intraoperatively during clinical interest prove efficacious advantageous. support gynaecological medical surgical community embrace efforts assist recruitment into randomised trials first relapse recurrent will provide answers questions establish would impact care